Zacks Research Has Negative Estimate for Neogen Q1 Earnings

Key Points

• Zacks Research has lowered its Q1 2026 earnings per share estimate for Neogen to $0.03, down from a previous forecast of $0.05, with a "Hold" rating on the stock.
• Neogen's current average stock rating is "Hold," with a consensus price target of $7.50, while the stock opened at $5.72.
• Institutional investors hold 96.73% of Neogen's stock, highlighting significant interest and investment from hedge funds and major investment firms.

Neogen Corporation (NASDAQ:NEOG - Free Report) - Equities research analysts at Zacks Research lowered their Q1 2026 EPS estimates for Neogen in a report issued on Wednesday, September 3rd. Zacks Research analyst Team now forecasts that the company will post earnings of $0.03 per share for the quarter, down from their previous forecast of $0.05. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen's Q2 2026 earnings at $0.07 EPS, FY2026 earnings at $0.27 EPS, Q2 2027 earnings at $0.08 EPS, Q4 2027 earnings at $0.08 EPS and Q1 2028 earnings at $0.07 EPS.

NEOG has been the subject of a number of other reports. William Blair lowered shares of Neogen from an "outperform" rating to a "market perform" rating in a report on Tuesday, July 29th. Guggenheim decreased their price target on shares of Neogen from $13.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, June 30th. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $7.50.

Neogen Stock Performance

Neogen stock opened at $5.72 on Thursday. The company has a current ratio of 3.32, a quick ratio of 2.22 and a debt-to-equity ratio of 0.42. The firm has a 50-day moving average of $5.21 and a 200-day moving average of $6.38. The firm has a market cap of $1.24 billion, a P/E ratio of -1.14 and a beta of 1.85. Neogen has a 1-year low of $3.87 and a 1-year high of $17.95.

Institutional Investors Weigh In On Neogen

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Neogen by 8.8% in the first quarter. Vanguard Group Inc. now owns 23,550,128 shares of the company's stock worth $204,180,000 after purchasing an additional 1,912,877 shares during the last quarter. Clarkston Capital Partners LLC lifted its stake in shares of Neogen by 123.2% during the 2nd quarter. Clarkston Capital Partners LLC now owns 14,005,725 shares of the company's stock valued at $66,947,000 after buying an additional 7,729,650 shares in the last quarter. Gates Capital Management Inc. purchased a new position in shares of Neogen during the 1st quarter valued at $79,391,000. Norges Bank purchased a new position in shares of Neogen during the 2nd quarter valued at $43,387,000. Finally, Conestoga Capital Advisors LLC lifted its stake in shares of Neogen by 0.4% during the 1st quarter. Conestoga Capital Advisors LLC now owns 8,540,859 shares of the company's stock valued at $74,049,000 after buying an additional 37,271 shares in the last quarter. Hedge funds and other institutional investors own 96.73% of the company's stock.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.